A novel multitarget stool RNA test for colorectal cancer screening achieved a sensitivity of 94% for CRC and 46% for advanced adenomas and a specificity of 88% for no lesions on colonoscopy, according to data from the CRC-PREVENT trial.
“The test demonstrated high sensitivity and specificity across all age groups, with significant improvement in sensitivity for colorectal neoplasia when compared to a FIT [fecal immunochemical test],” said senior investigator David S. Lieberman, MD, a